Distinguishing cancer-associated missense mutations from common polymorphisms

Cancer Research

Volumn 67, Issue 2, 2007, Pages 465-473

  Kaminker, Joshua S ^a   Zhang, Yan ^a   Waugh, Allison ^a   Haverty, Peter M ^a   Peters, Brock ^a   Sebisanovic, Dragan ^a   Stinson, Jeremy ^a   Forrest, William F ^a   Bazan, J Fernando ^b   Seshagiri, Somasekar ^a   Zhang, Zemin ^a,b  

^a Department of Bioinformatics ^*  (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CANCER GENETICS; CANCER GROWTH; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

ALGORITHMS; ALLELES; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DNA, NEOPLASM; EXPRESSED SEQUENCE TAGS; HUMANS; MUTATION, MISSENSE; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33846650692     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1736     Document Type: Article

References (51)

1. Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer 2004;4:177-83.
2. Stephens P, Edkins S, Davies H, et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 2005;37:590-2.
3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
4. O'Hare T, Pollock R, Stoffregen EP, et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 2004;104:2532-9.
5. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
6. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Scei U S A 2004;101:13306-11.
7. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
8. Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006;312:1228-30.
9. Landi MT, Bauer J, Pfeiffer RM, et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 2006;313:521-2.
10. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005;436:792.
11. Bonetta L. Going on a cancer gene hunt. Cell 2005;123:735-7.
12. Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003;300:949.
13. Wang ZC, Lin M, Wei LJ, et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 2004;64:64-71.
14. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004;3:1221-4.
15. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
16. Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005;65:7591-5.
17. Beckman RA, Loeb LA. Genetic instability in cancer: theory and experiment. Semin Cancer Biol 2005;15:423-35.
18. Lengauer C. Cancer. An unstable liaison. Science 2003;300:442-3.
19. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-37.
20. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
21. Aouacheria A, Navratil V, Wen W, et al. In silico whole-genome scanning of cancer-associated nonsynonymous SNPs and molecular characterization of a dynein light chain tumour variant. Oncogene 2005;24:6133-42.
22. Babenko VN, Basu MK, Kondrashov FA, Rogozin IB, Koonin EV. Signs of positive selection of somatic mutations in human cancers detected by EST sequence analysis. BMC Cancer 2006;6:36.
23. Bairoch A, Apweiler R, Wu CH, et al. The Universal Protein Resource (UniProt). Nucleic Acids Res 2005;33:D154-9.
24. Thomas PD, Kejariwal A. Coding single-nucleotide polymorphisms associated with complex vs. Mendelian disease: evolutionary evidence for differences in molecular effects. Proc Natl Acad Sci U S A 2004;101:15398-403.
25. Forbes S, Clements J, Dawson E, et al. Cosmic 2005. Br J Cancer 2006;94:318-22.
26. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812-4.
27. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002;30:3894-900.
28. Clifford RJ, Edmonson MN, Nguyen C, Buetow KH. Large-scale analysis of non-synonymous coding region single nucleotide polymorphisms. Bioinformatics 2004;20:1006-14.
29. Karchin R, Diekhans M, Kelly L, et al. LS-SNP: large-scale annotation of coding non-synonymous SNPs based on multiple information sources. Bioinformatics 2005;21:2814-20.
30. Barenboim M, Jamison DC, Vaisman II. Statistical geometry approach to the study of functional effects of human nonsynonymous SNPs. Hum Mutat 2005;26:471-6.
31. Yue P, Moult J. Identification and analysis of deleterious human SNPs. J Mol Biol 2006;356:1263-74.
32. Krishnan VG, Westhead DR. A comparative study of machine-learning methods to predict the effects of single nucleotide polymorphisms on protein function. Bioinformatics 2003;19:2199-209.
33. Bao L, Cui Y. Prediction of the phenotypic effects of non-synonymous single nucleotide polymorphisms using structural and evolutionary information. Bioinformatics 2005;21:2185-90.
34. Wang Z, Shen D, Parsons DW, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004;304:1164-6.
35. Wu TD, Watanabe CK. GMAP: a genomic mapping and alignment program for mRNA and EST sequences. Bioinformatics 2005;21:1859-75.
36. Bateman A, Birney E, Durbin R, Eddy SR, Finn RD, Sonnhammer EL. Pfam 3.1: 1313 multiple alignments and profile HMMs match the majority of proteins. Nucleic Acids Res 1999;27:260-2.
37. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244:217-21.
38. Teng DH, Hu R, Lin H, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997;57:5221-5.
39. Milde-Langosch K, Ocon E, Becker G, Loning T. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hypermethylation or mutation in endometrioid and mucinous tumors. Int J Cancer 1998;79:61-5.
40. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
41. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
42. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92:10560-4.
43. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
44. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
45. Bardelli A, Velculescu VE. Mutational analysis of gene families in human cancer. Curr Opin Genet Dev 2005;15:5-12.
46. Diaz-Uriarte R, Alvarez de Andres S. Gene selection and classification of microarray data using random forest. BMC Bioinformatics 2006;7:3.
47. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74.
48. SeattleSNPs. NHLBI program for genomic applications: 2006.
49. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33.
50. Benvenuti S, Arena S, Bardelli A. Identification of cancer genes by mutational profiling of tumor genomes. FEBS Lett 2005;579:1884-90.
51. Furney SJ, Higgins DG, Ouzounis CA, Lopez-Bigas N. Structural and functional properties of genes involved in human cancer. BMC Genomics 2006;7:3.